Key statistics
On Friday, Roche Holding AG (ROGN:MEX) closed at 6,003.81, -8.76% below its 52-week high of 6,580.00, set on Sep 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6,003.81 |
---|---|
High | 6,003.81 |
Low | 6,003.81 |
Bid | -- |
Offer | -- |
Previous close | 6,003.81 |
Average volume | 43.00 |
---|---|
Shares outstanding | 809.25m |
Free float | 724.65m |
P/E (TTM) | 20.22 |
Market cap | 218.47bn CHF |
EPS (TTM) | 13.23 CHF |
Annual div (ADY) | 181.42 MXN |
---|---|
Annual div yield (ADY) | 3.02% |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 20 minutes, as of Sep 13 2024 19:38 BST.
More ▼
- Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
- FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
- FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
- Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen
- Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
- Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
- Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
- Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
- European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
- Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
More ▼